Weight Loss and Improvement of Metabolic Alterations in Overweight and Obese Children Through the I2AO2 Family

Virginia E Fernández-Ruiz1,2, Maria Solé-Agustí3, David Armero-Barranco2

  • 1Department of Endocrinology and Nutrition, Virgen de la Arrixaca University Clinic Hospital Murcia, Spain.

Insights

A multidisciplinary program significantly reduced childhood obesity and improved metabolic health. This nurse-led intervention showed lasting positive effects on weight and key health markers 12 months post-treatment.

Area of Science:

  • Pediatrics
  • Public Health
  • Metabolic Health

Background:

  • Childhood obesity presents a significant global public health challenge.
  • Effective interventions are crucial for managing pediatric overweight and obesity.
  • Metabolic complications associated with excess weight require targeted management strategies.

Purpose of the Study:

  • To evaluate a multidisciplinary program's effectiveness in treating childhood obesity.
  • To assess the program's impact on weight reduction and metabolic parameters.
  • To determine the long-term sustainability of intervention effects.

Main Methods:

  • A 24-month randomized controlled trial involving 108 children aged 6-12 years.
  • An experimental group received a 12-month interdisciplinary program (diet, exercise, CBT, education).
  • A control group received standard care; measurements taken at 4, 12, and 24 months.

Main Results:

  • Significant reductions in body mass index, skinfolds, waist, and arm circumferences.
  • Marked improvements in metabolic markers: decreased total cholesterol, LDL-C, triglycerides, and hyperglycemia.
  • Significant increase in HDL-C observed.
  • Sustained positive effects on anthropometric and biochemical markers 12 months post-intervention.

Conclusions:

  • An interdisciplinary, nurse-led program effectively reduces excess weight and obesity in children.
  • The program promotes sustained healthy lifestyle changes with long-lasting health benefits.
  • This intervention offers a promising approach for managing pediatric obesity and associated metabolic risks.

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
925
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
85
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
78
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
109
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
89
Energy Balance01:19

Energy Balance

The human body gets energy from the three macronutrients: carbohydrates, proteins, and fats. Energy is released when the chemical bonds in the organic compounds present in the food are broken down. The energy content of food is measured in kilocalories (kcal), defined as the amount of heat required to raise the temperature of one kilogram of water by one degree Celsius. This value is determined by measuring the temperature change of the water surrounding a calorimeter after the complete...
771